Global diabetes monitoring devices market size is expected to reach USD 23.74 Bn by 2032, from USD 13.5 Bn in 2025, exhibiting a compound annual growth rate (CAGR) of 8.4% during the forecast period.
The diabetes monitoring devices market demand continues to grow as the market is bifurcated into self-monitoring blood glucose devices and continuous glucose monitoring devices. These devices are used to track blood sugar levels throughout the day and night, enabling individuals to make informed choices about food, physical activity, and medication. Blood sugar levels can be effectively monitored and tracked using assistive medical technologies known as diabetes monitoring or blood glucose monitoring devices. These devices cater to patients with both type I and type II diabetes, further driving the demand across diverse patient demographics.
|
Current Event |
Description and its Impact |
|
Regulatory Transformation and Coverage Expansion |
|
|
Global Population Screening and Early Detection Initiatives |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Artificial Intelligence (AI) is transforming the Diabetes Monitoring Devices Market by enabling smarter, more personalized care. AI-powered systems analyze vast amounts of glucose data to detect patterns, predict blood sugar fluctuations, and offer real-time insights. This enhances decision-making for both patients and healthcare providers, improving treatment outcomes. Integration with mobile apps and cloud platforms allows seamless data sharing and remote monitoring, while machine learning algorithms continuously refine accuracy and responsiveness. As AI continues to evolve, it is expected to drive innovation in non-invasive monitoring, early diagnosis, and automated insulin delivery, making diabetes management more proactive and efficient.
For instance, in May 2025, IBM and Roche introduced an AI-powered app designed to predict blood sugar levels, marking a breakthrough in diabetes management. The app enables proactive care by analyzing patterns and offering personalized insights, helping users manage their condition more effectively and reduce complications through smarter, data-driven decision-making.
In terms of product type, the Continuous Glucose Monitoring (CGM) devices segment is expected to hold 56.8% share in 2025. These devices provide real-time glucose readings, trend analysis, and customizable alerts, offering a more dynamic and responsive approach to diabetes management compared to traditional Self-Monitoring Blood Glucose (SMBG) devices. The surge in CGM adoption is fueled by growing patient awareness, rapid technological advancements, and seamless integration with insulin pumps and mobile health applications. Their ability to reduce hypoglycemic episodes and improve glycemic control makes CGMs a preferred choice among both patients and healthcare providers.
For instance, in August 2025, Abbott launched its advanced FreeStyle Libre 2 Plus glucose monitoring system in India, offering continuous glucose readings every minute and optional alarms for enhanced diabetes management. This next-gen device aims to empower users with real-time insights and improved control, reinforcing Abbott’s commitment to innovative healthcare solutions.
In terms of indication, the Type-II diabetes segment is expected to contribute the largest share of the market in 2025. This is largely due to its widespread prevalence, particularly among aging populations and individuals with sedentary lifestyles. As Type-II Diabetes accounts for the majority of global diabetes cases, the demand for effective and accessible monitoring solutions is substantial. According the U.S. Centers of Disease Control and Prevention, more than 38 million Americans have diabetes (about 1 in 10), and about 90% to 95% of them have type 2 diabetes. The increasing focus on early detection, lifestyle management, and long-term disease control has amplified the need for reliable monitoring devices tailored to this demographic, making it a key driver of market growth.
For instance, in September 2025, Medtronic’s MiniMed 780G system received FDA clearance for use in Type 2 diabetes and integration with Abbott’s Instinct sensor. This milestone marks a significant step in automated insulin delivery, offering enhanced glucose management through real-time sensor data and expanding access to advanced diabetes care technologies.
In terms of end user, the Home Care Setting segment is projected to account for the highest share of the market in 2025, reflecting a broader shift toward decentralized and patient-centric healthcare. The convenience of monitoring blood glucose levels from home, coupled with the rise of telehealth services and remote patient monitoring, has made home-based solutions highly attractive. User-friendly interfaces, portable designs, and digital connectivity have empowered patients to take control of their health, reducing the need for frequent clinical visits. This trend is particularly impactful for chronic disease management, where continuous monitoring and timely interventions are crucial.
For instance, in July 2025, UMass Diabetes Center of Excellence released a comprehensive update on emerging diabetes technologies, highlighting advancements in continuous glucose monitoring, automated insulin delivery systems, and digital health tools. The center emphasizes improved patient outcomes, accessibility, and integration of smart devices, reflecting a growing shift toward personalized and tech-driven diabetes care.
To learn more about this report, Download Free Sample
North America is expected to be the largest market for diabetes monitoring devices market during the forecast period, accounting for over 35.8% of the market share in 2025, due to the region's high diabetes prevalence, advanced healthcare infrastructure, and early adoption of innovative technologies like CGMs. Supportive reimbursement policies, growing awareness, and the presence of key market players further drive demand, making North America a dominant force in global diabetes care solutions.
For instance, in April 2025, Dexcom secured FDA clearance for its G7 continuous glucose monitoring system, now approved for 15-day wear. This advancement offers users extended sensor life, reducing replacements and enhancing convenience. The G7’s streamlined design and real-time data capabilities mark a significant step forward in personalized diabetes management and long-term glucose tracking.
The Asia Pacific market is expected to be the fastest-growing market for diabetes monitoring devices market, with a CAGR of over 8.0% during the forecast period, due to rising diabetes prevalence, urbanization, and lifestyle changes. Increasing healthcare awareness, expanding middle-class populations, and supportive government initiatives are driving demand. Additionally, the adoption of digital health technologies and improved access to affordable monitoring devices are fueling market expansion across emerging economies in the region.
For instance, in September 2025, at the 3rd Borneo Diabetes Conference, BUZUD unveiled its AI-driven continuous glucose monitoring system, designed to enhance real-time diabetes management. The innovative device leverages artificial intelligence to deliver precise glucose readings, aiming to empower patients with smarter, more personalized care solutions in both clinical and home settings.
The U.S. Diabetes Monitoring Devices Market is booming due to high diabetes prevalence, advanced healthcare infrastructure, and strong consumer adoption of tech-driven solutions. Favorable reimbursement policies, rising awareness, and FDA approvals for innovative devices like CGMs and automated insulin systems further fuel demand, positioning the U.S. as a global leader in diabetes care.
For instance, in October 2025, Walmart planned to sell Abbott’s Lingo over-the-counter glucose monitor, expanding access to real-time metabolic tracking without a prescription. The move marks a major step in consumer health tech, enabling users to monitor glucose levels conveniently and proactively manage wellness through affordable, AI-powered insights available at retail locations nationwide.
China’s Diabetes Monitoring Devices Market is expanding due to a surge in Type 2 diabetes cases, driven by urbanization, aging population, and changing lifestyles. Increased health awareness, government support for digital health, and rising adoption of continuous glucose monitoring systems are fueling demand, making China a key player in the global diabetes care landscape.
For instance, in September 2025, Innovent Biologics received approval from China’s National Medical Products Administration (NMPA) for Mazdutide, a novel therapy for glycemic control in adults with Type 2 diabetes. This milestone marks a significant advancement in China’s diabetes treatment landscape, offering new options for effective and personalized disease management.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 13.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.4% | 2032 Value Projection: | USD 23.74 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
i-SENS, Inc., Ascensia Diabetes Care Holdings AG., Bayer AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Medtronic, Dexcom, Abbott, Labiotech UG, ARKRAY, Inc., Cnoga, Sanofi, and Lifescan |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The diabetes monitoring devices market is transitioning from hardware-driven innovation to an ecosystem model defined by data integration, payer alignment, and clinical workflow ownership. Continuous glucose monitoring (CGM) has now achieved clinical validation beyond specialist use, studies show a ~22% increase in Time-In-Range (from 39.7% to 61.9%), underscoring its significant impact on glycemic control and complication reduction. However, adoption remains concentrated in high-income markets, with coverage gaps limiting access for most of the global diabetes population.
Competition is consolidating, led by platform players such as Abbott, Dexcom, and Medtronic, which combine sensor technology with data analytics and reimbursement networks. Incremental sensor accuracy improvements are no longer decisive; software-driven differentiation, including AI analytics, pump integration, and telehealth compatibility will shape long-term leadership. Reimbursement remains the pivotal determinant of uptake, as payers increasingly link device funding to proven outcome improvements and cost savings.
In emerging economies, affordability and infrastructure gaps demand localized models such as pay-as-you-go or government-backed programs. Ultimately, commercial success will hinge on health economics evidence, interoperable software ecosystems, and adaptive market access strategies, transforming diabetes monitoring from a device business into a digital health platform anchored in measurable patient outcomes and cost-effectiveness.
Definition: Blood glucose monitoring is the use of a glucose meter for testing the concentration of glucose in the blood. It is particularly important in diabetes management which includes a blood glucose test that is typically performed by piercing the skin to draw blood, and then by applying the blood to a chemically active disposable 'test-strip'.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
